Luciferin IPA-based higher throughput human hepatocyte screening assays for CYP3A4 inhibition and induction

Journal of Biomolecular Screening

Volumn 16, Issue 8, 2011, Pages 903-909

  Doshi, Utkarsh ^a   Li, Albert P ^a  

^a In Vitro ADMET Laboratories LLC   (United States)

Author keywords

CYP3A; Drug drug interactions; Human hepatocytes; P450 induction; P450 inhibition

Indexed keywords

1 AMINOBENZOTRIAZOLE; CARBAMAZEPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DIETHYLDITHIOCARBAMIC ACID; ERYTHROMYCIN; ISOPROTEIN; KETOCONAZOLE; LUCIFERIN; LUCIFERIN IPA; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PIOGLITAZONE; QUERCETIN; QUINIDINE; RIFAMPICIN; ROSIGLITAZONE; SULFAPHENAZOLE; TICLOPIDINE; TRANYLCYPROMINE; TROGLITAZONE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; BIOASSAY; CELL ISOLATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; CRYOPRESERVATION; DRUG SCREENING; ENZYME SUBSTRATE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LIVER CELL; PRIORITY JOURNAL; PROTEIN METABOLISM; SENSITIVITY AND SPECIFICITY;

AUTOMATION, LABORATORY; BIOLOGICAL AGENTS; CELL SURVIVAL; CELLS, CULTURED; CRYOPRESERVATION; CYTOCHROME P-450 CYP3A; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; FIREFLY LUCIFERIN; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 80054718270     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057111414900     Document Type: Article

References (29)

1. Lin, J. FL; Lu, A. Y. Inhibition and Induction of Cytochrome P450 and the Clinical implications. Clin. Pharmacokinet. 1998, 35, 361-390. (Pubitemid 28520008)
2. Vazquez, E.; Whitfield, L. Seldane Warnings. Posit. Aware. 1997, 8, 12.
3. Carlson, A. M.; Morris, L. S. Coprescription of Terfenadine and Erythromycin or Ketaconazole: An Assessment of Potential Harm. J. Am. Pharm. Assoc. (Wash.) 1996, NS36, 263-269. (Pubitemid 26124982)
4. Lin, J. H. CYP Induction-Mediated Drug Interactions: In Vitro Assessment and Clinical Implications. Pharm. Res. 2006, 23, 1089-1116. (Pubitemid 43946134)
5. Skolnick, J. L.; Stoler, B. S.; Katz, D. B.; Anderson, W. H. Rifampin, Oral Contraceptives, and Pregnancy. JAMA 1976, 236, 1382.
6. Molden, E.; Skovlund, E.; Braathen, P. Risk Management of Simvastatin or Atorvastatin Interactions with CYP3A4 Inhibitors. Drug Saf. 2008, 31, 587-596. (Pubitemid 351861951)
7. Zhang, L.; Zhang, Y. D.; Zhao, P.; Huang, S. M. Predicting Drug-Drug Interactions: An FDA Perspective. AAPS J. 2009, 11, 300-306.
8. Davit, B.; Reynolds, K.; Yuan, R.; Ajayi, F.; Conner, D.; Fadiran, E.; Gillespie, B.; Sahajwalla, C.; Huang, S. M.; Lesko, L. J. FDA Evaluations Using In Vitro Metabolism to Predict and Interpret In Vivo Metabolic Drug-Drug Interactions: Impact on Labeling. J. Clin. Pharmacol. 1999, 39, 899-910. (Pubitemid 30644025)
9. Balian, J. D.; Rahman, A. Metabolic Drug-Drug Interactions: Perspective from FDA Medical and Clinical Pharmacology Reviewers. Adv. Pharmacol. 1997, 43, 231-238.
10. Amarneh, B.; Simpson, E. R. Expression of a Recombinant Derivative of Human Aromatase P450 in Insect Cells Utilizing the Baculovirus Vector System. Mol. Cell. Endocrinol. 1995, 109, R1-R5.
11. Guengerich, F. P. Cytochrome p450 and Chemical Toxicology. Chem. Res. Toxicol. 2008, 21, 70-83. (Pubitemid 351219709)
12. Zhou, S. F. Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4. Curr. Drug Metab. 2008, 9, 310-322.
13. Cailliatte, R.; Lapeyre, B.; Briat, J. F.; Mari, S.; Curie, C. The NRAMP6 Metal Transporter Contributes to Cadmium Toxicity. Biochem. J. 2009, 422, 217-228.
14. Yin, H.; Racha, J.; Li, S. Y.; Olejnik, N.; Satoh, H.; Moore, D. Automated High Throughput Human CYP isoform Activity Assay Using SPE-LC/MS Method: Application in CYP Inhibition Evaluation. Xenobiotica 2000, 30, 141-154. (Pubitemid 30125115)
15. Aryal, P.; Yoshikawa, K.; Terashita, T.; Guengerich, F. P.; Shimada, T.; Oda, Y. Development of a New Genotoxicity Test System with Salmonella typhimurium OY1001/1A2 Expressing Human CYP1A2 and NADPH-P450 Reductase. Mutat. Res. 1999, 442, 113-120. (Pubitemid 29313432)
16. Kariv, I.; Fereshteh, M. P.; Oldenburg, K. R. Development of a Miniaturized 384-Well High Throughput Screen for the Detection of Substrates of Cytochrome P450 2D6 and 3A4 Metabolism. J. Biomol. Screen. 2001, 6, 91-99. (Pubitemid 32373800)
17. Bell, L.; Bickford, S.; Nguyen, P. H.; Wang, J.; He, T.; Zhang, B.; Friche, Y.; Zimmerlin, A.; Urban, L.; Bojanic, D. Evaluation of Fluorescence-and Mass Spectrometry-Based CYP Inhibition Assays for Use in Drug Discovery. J. Biomol. Screen. 2008, 13, 343-353. (Pubitemid 351793985)
18. Lim, K. B.; Ozbal, C. C.; Kassel, D. B. Development of a High-Throughput Online Solid-Phase Extraction/Tandem Mass Spectrometry Method for Cytochrome P450 Inhibition Screening. J. Biomol. Screen. 2010, 15, 447-452.
19. Loretz, L. J.; Li, A. P.; Flye, M. W.; Wilson, A. G. Optimization of Cryopreservation Procedures for Rat and Human Hepatocytes. Xenobiotica 1989, 19, 489-498. (Pubitemid 19128871)
20. Li, A. P.; Lu, C.; Brent, J. A.; Pham, C.; Fackett, A.; Ruegg, C. E.; Silber, P. M. Cryopreserved Human Hepatocytes: Characterization of Drug-Metabolizing Enzyme Activities and Applications in Higher Throughput Screening Assays for Hepatotoxicity, Metabolic Stability, and Drug-Drug Interaction Potential. Chem. Biol. Interact. 1999, 121, 17-35. (Pubitemid 29240667)
21. Li, A. P. Human Hepatocytes: Isolation, Cryopreservation and Applications in Drug Development. Chem. Biol. Interact. 2007, 168, 16-29. (Pubitemid 46659921)
22. Eagling, et al.
23. Li, A. P. Human Hepatocytes as an Effective Alternative Experimental System for the Evaluation of Human Drug Properties: General Concepts and Assay Procedures. ALTEX 2008, 25, 33-42.
24. Crespi, C. L.; Miller, V. P.; Penman, B. W. Microtiter Plate Assays for Inhibition of Human, Drug-Metabolizing Cytochromes P450. Anal. Biochem. 1997, 248, 188-190. (Pubitemid 27218241)
25. Chauret, N.; Tremblay, N.; Lackman, R. L.; Gauthier, J. Y.; Silva, J. M.; Marois, J.; Yergey, J. A.; Nicoll-Griffith, D. A. Description of a 96-Well Plate Assay to Measure Cytochrome P4503A Inhibition in Human Liver Microsomes Using a Selective Fluorescent Probe. Anal. Biochem. 1999, 276, 215-226. (Pubitemid 30013043)
26. Parkinson, A.; Kazmi, F.; Buckley, D. B.; Yerino, P.; Ogilvie, B. W.; Paris, B. L. System-Dependent Outcomes during the Evaluation of Drug Candidates as Inhibitors of Cytochrome P450 (CYP) and Uridine Diphosphate Glucuronosyltransferase (UGT) Enzymes: Human Hepatocytes versus Liver Microsomes versus Recombinant Enzymes. Drug Metab. Pharmacokinet. 2010, 25, 16-27.
27. Shitara, Y.; Itoh, T.; Sato, H.; Li, A. P.; Sugiyama, Y. Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A. J. Pharmacol. Exp. Ther. 2003, 304, 610-616. (Pubitemid 36152336)
28. Kaneko, A.; Kato, M.; Endo, C.; Nakano, K.; Ishigai, M.; Takeda, K. Prediction of Clinical CYP3A4 Induction Using Cryopreserved Human Hepatocytes. Xenobiotica 2010, 40, 791-799.
29. Fahmi, O. A.; Kish, M.; Boldt, S.; Obach, R. S. Cytochrome P450 3A4 mRNA Is a More Reliable Marker Than CYP3A4 Activity for Detecting Pregnane X Receptor-Activated Induction of Drug-Metabolizing Enzymes. Drug Metab. Dispos. 2010, 38, 1605-1611.